EcoDrugPlus

Potassium Two Pore Domain Channel Subfamily K Member 3

Ensembl ID : ENSEEUG00000009181
Gene Symbol: KCNK3
1 External references
202 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSEEUG00000010863
Gene Symbol: KCNK9
3 External references
215 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSEEUG00000000483
Gene Symbol: KCND3
1 External references
261 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSEEUG00000012972
Gene Symbol: KCNQ3
1 External references
193 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSEEUG00000003046
Gene Symbol: KCNQ5
1 External references
200 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSEEUG00000007027
Gene Symbol: PSEN1
1 External references
202 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSEEUG00000013761
Gene Symbol: PSEN2
1 External references
205 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSEEUG00000002930
Gene Symbol: PSENEN
3 External references
184 Possible Orthologues:

Prostaglandin D2 Receptor

Ensembl ID : ENSEEUG00000004286
Gene Symbol: PTGDR
3 External references
118 Possible Orthologues:

Prostaglandin E Receptor 2

Ensembl ID : ENSEEUG00000009135
Gene Symbol: PTGER2
1 External references
244 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSEEUG00000012887
Gene Symbol: PTGER3
1 External references
196 Possible Orthologues:

Prostaglandin F Receptor

Ensembl ID : ENSEEUG00000001054
Gene Symbol: PTGFR
1 External references
195 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).